Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase by Dong, Yunzhou et al.
Introduction
Metabolic syndrome and type 2 diabetes are insulin-resistant
states that are commonly associated with atherogenic dyslipi-
daemia involving mild to moderate elevation of triglycerides,
low levels of high-density lipoprotein cholesterol (HDL-C) and a
preponderance of small dense low-density lipoprotein (LDL)
[1]. Elevated LDL is a classical risk factor for atherosclerotic
cardiovascular disease. In diabetes, elevation of LDL is exacer-
bated by qualitative modifications, including glycation and oxi-
dation. Native LDL (N-LDL), which is found in the plasma of
healthy individuals, becomes glycated (glycated LDL) in the
plasma of diabetic patients. After extravasation and prolonged
entrapment in the arterial sub-intimal space, this glycated LDL
may become severely oxidized [2], and in the present work this
form of modified (i.e. glycated, then oxidized) LDL is represent-
ed by an in vitro preparation of ‘heavily oxidized’ glycated LDL
(HOG-LDL). The pro-inflammatory and pro-atherogenic effects
of oxidized LDL as well as the close involvement of modified
form of LDL in the initiation and progression of atherosclerosis
are well established [3]. In diabetes, hyperglycaemia increases
not only glycation but also oxidative stress, resulting in oxida-
tion of proteins, lipids and DNA or modification of these macro-
molecules with covalent adducts [4, 5]. Glycation of LDL slows
the clearance of the particles from the blood circulation [6]
increases the susceptibility of particles to oxidative damage [7],
enhances entrapment of extravasated particles in the sub-inti-
mal space and increases chemotactic activity of monocytes [8].
For these reasons, glycation of LDL is intimately connected with
the formation of oxidized LDL.
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Abstract
Oxidation and glycation of low-density lipoprotein (LDL) promote vascular injury in diabetes; however, the mechanisms underlying this
effect remain poorly defined. The present study was conducted to determine the effects of ‘heavily oxidized’ glycated LDL (HOG-LDL)
on endothelial nitric oxide synthase (eNOS) function. Exposure of bovine aortic endothelial cells with HOG-LDL reduced eNOS protein
levels in a concentration- and time-dependent manner, without altering eNOS mRNA levels. Reduced eNOS protein levels were accom-
panied by an increase in intracellular Ca
2, augmented production of reactive oxygen species (ROS) and induction of Ca
2-dependent
calpain activity. Neither eNOS reduction nor any of these other effects were observed in cells exposed to native LDL. Reduction of intra-
cellular Ca
2 levels abolished eNOS reduction by HOG-LDL, as did pharmacological or genetic through calcium channel blockers or cal-
cium chelator BAPTA or inhibition of NAD(P)H oxidase (with apocynin) or inhibition of calpain (calpain 1-specific siRNA). Consistent
with these results, HOG-LDL impaired acetylcholine-induced endothelium-dependent vasorelaxation of isolated mouse aortas, and phar-
macological inhibition of calpain prevented this effect. HOG-LDL may impair endothelial function by inducing calpain-mediated eNOS
degradation in a ROS- and Ca
2-dependent manner.
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Injury to vascular endothelial cells is implicated in atheroscle-
rosis and thrombosis [9]. Under normal conditions, endothelial
nitric oxide synthase (eNOS) generates the vasoprotective mole-
cule, nitric oxide [9, 10]. Vascular nitric oxide has a variety of
functions, the most important being dilation of all types of blood
vessels to maintain vascular homeostasis [10]. In atherosclerosis,
a reduction in eNOS-derived nitric oxide impairs endothelium-
dependent relaxation, with this impairment occurring before vas-
cular structural changes arise [11]. Type 2 diabetes is associated
not only with oxidant stress and accelerated endothelial apoptosis,
but also with impaired endothelium-dependent relaxation [12, 13].
Indeed, endothelial dysfunction characterized by reduced nitric
oxide bioactivity is a critical component of accelerated atheroscle-
rosis associated with type 2 diabetes. Both hyperglycaemia and
dyslipoproteinemia have also been implicated in the acceleration
of diabetic vascular complications.
Oxidized LDL promotes endothelial cell toxicity and vasocon-
striction both in vitro and in vivo. Plasma levels of oxidized LDL
correlate with endothelial dysfunction and are reduced following
lipid-lowering therapy using apheresis or statins (reviewed by
Navab et al. [14]). Plasma levels of oxidized LDL were also recently
shown to be an independent determinant of coronary macrovaso-
motor and microvasomotor responses elicited by bradykinin in
human beings [15]. Circulating levels of oxidized LDL have been
proposed to be a predictor of secondary cardiovascular events
[16]. However, the molecular mechanisms by which HOG-LDL
impairs endothelial dysfunction are poorly understood. Thus, the
aim of the present study was to determine the effects of HOG-LDL
on eNOS function by isolating LDL from healthy donors and then
modifying it in vitro. Here, we demonstrate that HOG-LDL triggers
endothelial dysfunction via Ca
2-mediated, calpain-dependent
eNOS degradation.
Materials and methods
Materials
MDL 28170 (carbobenzoxyl-valinyl-phenylalaninal) was purchased from
Calbiochem (Gibbstown, NJ, USA). Other calpain inhibitors (ALLN, ALLM,
calpeptin and E-64) and the fluorescent calpain substrate, Suc-leu-Leu-
Val-Tyr-AMC, were obtained from BioMol International (Plymouth Meeting,
PA, USA). The Fluo-4 NW calcium assay kits, dihydroethidium (DHE) and
2,7-dichlorofluorescein (DCF) were obtained from Invitrogen (Carlsbad,
CA, USA). Antibodies against eNOS, phospho-Ser1177 of eNOS and 3-
nitrotyrosine-specifc antibody were obtained from Cell Signaling
Technology (Danvers, MA, USA). Calpain 1 antibody, calpain 1-specific
siRNA and scrambled siRNA were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Recombinant eNOS and 4, 5-
diaminofluorescein (DAF-2) were obtained from Cayman Chemical (Ann
Arbor, MI, USA). Calcium channel blockers (CoCl2, LaCl3, Verapamil),
diphenyleneiodonium chloride (DPI) and 4-hydroxy-3-methoxyacetophe-
none (apocynin) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). All other chemicals were from Fisher Scientific (Pittsburgh, PA,
USA) and were of the highest available grade.
Animals
C57BL/6J mice aged 10 weeks were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA). Mice were housed in temperature-controlled cages
under a 12-hr light/dark cycle and were given free access to water and
food. The animal protocol was reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Oklahoma Health
Sciences Center.
Preparation of N-LDL and HOG-LDL
The isolation of LDL from human donors was approved by the Institutional
Review Board at the University of Oklahoma Health Science Center. Both N-
LDL and HOG-LDL were prepared as previously described [17].
Cell culture and treatment
Bovine aortic endothelial cells (BAECs) at passage 10 were cultured in
endothelial basal medium (EBM; Lonza, Walkersville, MD, USA) containing
2% fetal bovine serum (FBS). Confluent BAECs were treated with the indi-
cated concentration of HOG-LDL for varying times. When required, BAECs
were exposed to BAPTA-AM (1,2-bis-[o-Aminophenoxy]-ethane-N,N,N’,N’-
tetraacetic acid, tetraacetoxymethyl ester), EGTA, calpain inhibitors, Ca
2
channel blockers and NADPH oxidase inhibitors for 0.5–1 hr prior to the
addition of HOG-LDL. BAECs treated with N-LDL (100 g/ml, which is
believed to be the physiological concentration) served as controls.
Measurement of eNOS dimers/monomers
Levels of eNOS dimers/monomers were assayed using low-temperature
SDS-PAGE, without boiling samples, as previously described [18].
Immunocytochemical staining of eNOS and 
calpain 1
Calpain 1 and eNOS immunostaining was performed as described else-
where [19]. Briefly, BAECs were cultured on cover slips and fixed with 4%
paraformaldehyde. After blocking, BAECs were incubated with a mouse
anti-eNOS antibody (BD Transduction Laboratories, San Jose CA, USA), or
rabbit anti-calpain 1 antibody overnight at 4°C. Cell and tissue sections
were then incubated for 30 min. at room temperature with biotinylated
antimouse or anti-rabbit IgG secondary antibodies. The slides were rinsed,
incubated with Fluorescein Avidin D (Vector Laboratories, Burlingame, CA,
USA) for 30 min., counterstained with 4,6-diamidino-2-phynylindole
(DAPI), mounted in Vectashield
TM mounting media (Vector Laboratories)
and viewed on a SLM 510 laser scanning confocal microscope (CARL
Zeiss Meditec, Inc., Jena, Germany).
Measurement of reactive oxygen species
Reactive oxygen species (ROS) were assayed using DHE (for superoxide
[O2
]) and DCF (for hydrogen peroxide [H2O2]) fluorescent dyes as
described previously [18, 20].
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Reverse transcription and real-time quantitative
PCR (qPCR)
After treatment with N-LDL or HOG-LDL, BAECs were repeatedly washed
and total RNA was extracted (RNeasy Mini Kit, Qiagen, Valencia, CA, USA).
RNA concentrations were determined using the NanoDrop
® ND-1000 UV-
Vis Spectrophotometer. Reverse transcription was performed with 1 g of
total RNA using the ThermoScript RT-PCR System (Invitrogen, cat#
11146-024), according to the manufacturer’s protocol. SYBR Green real-
time PCR primers used for amplification of bovine eNOS (GeneBank
Access No. M99057) and bovine GAPDH (GeneBank Access No.
NP_001029206) were as follows: eNOS, forward 5-TACCAGCCGG
GGGACCACATAGGC-3, reverse 5-CTCCAGCTGCTCCACAGCCACAGAC-3;
GAPDH, forward 5-GCAGACGGTGCAGCGCATCTTGG-3, reverse 5-
TGGGTACGTATACGGCTTGTCAC-3. qPCR was performed on 2 l/well of
reverse-transcribed product (20 ng total RNA) using the iQ TM SYBR
®
Green Supermix kit (Bio-Rad, Hercules, CA, USA, cat# 170-8882). The
qPCR mixture was heated to 95°C for 3 min. and then subjected to 40
cycles at 95°C for 30 sec., 57°C for 30 sec. and 72°C for 1 min. using the
MyiQTM System (Bio-Rad). The cycle threshold (Ct) value was determined
for each sample. All Ct values were normalized to the internal control gene
GAPDH (Ct   CPtarget  CPcontrol). The relative expression of eNOS
mRNA, as determined by Ct value, was calculated using the equation,
2
Ct [21].
Measurement of intracellular calcium
Intracellular Ca
2 concentration was measured using the Fluo-4 NW kit,
according to the instruction from the manufacturer, and the relative fluo-
rescent units of intracellular calcium was expressed as fold induction over
control.
Measurement of calpain activity
Calpain activity assays were performed with a previously described
method with minor modification [22]. Briefly, culture medium was aspirat-
ed from N-LDL or HOG-LDL-treated BAECs, and cells were washed with
Hepes buffer (Invitrogen, pH 7.4). Cells were then incubated with Suc-leu-
Leu-Val-Tyr-AMC in Hepes buffer for 30 min., and fluorescence was
recorded (Ex: 360  20 nm, Em: 460  20 nm). Calpain activation was
confirmed by monitoring cleavage of the calpain substrate, caspase-12, by
Western blot.
Measurement of 26S proteasome activity
The 26S proteasome activity was assayed using the fluorogenic protea-
some substrate, Suc-LLVY-7-amido-4-methylcoumarin, as detailed previ-
ously [23].
Transfection of calpain 1-specific siRNA
After serum deprivation for 24 hrs, confluent human umbilical vein
endothelial cells (HUVECs) were transfected with calpain 1-specific siRNA
or scrambled siRNA according to the manufacturer’s instructions. Forty-
eight hours later, HUVECs were lysed for Western blot analysis of calpain
1 and eNOS.
Measurement of nitric oxide
BAECs were cultured in EBM medium overnight in 24-well plates and incu-
bated in N- or HOG-LDL for an additional 6 hrs. Cells were then incubated
in phenol red-free EBM medium containing 2.5 M DAF-2 for 30 min. in a
CO2 incubator. Nitric oxide levels were determined by measuring fluores-
cence (Ex/Em: 495/515 nm) and were expressed as a percentage of fluo-
rescence emitted by control cultures.
Measurement of endothelium-dependent 
and -independent vasorelaxation
Aortas were isolated from mice, cut into 3-mm rings and mounted in organ
chambers (PowerLab, AD Instruments, CO, USA) in Kreb’s buffer. After a
60-min. equilibration, rings were exposed to N-LDL or HOG-LDL (100
g/ml each) in the absence or presence of the calpain inhibitor,
MDL28170. Six hours later, rings were washed and pre-contracted with
U46619 (30 nmol/l). Vasodilation responses were determined through the
addition of 0.01 to 100 M acetylcholine (Ach) or 0.0001 to 1 M sodium
nitroprusside (SNP), as described previously [23].
Western blot analysis
Total proteins were analysed by SDS-PAGE and blotted using standard pro-
tocols [24]. Densitometric quantification was performed with Quantity One
software (Bio-Rad). Protein levels (arbitrary units) were normalized to 	-
actin and expressed as percentage of control values.
Statistics
All values are expressed as mean  standard deviation, unless noted oth-
erwise. Endothelium-dependent relaxation was analysed using a two-way
ANOVA, followed by multiple t-tests. All other results were analysed using
the Student’s t-test. The value P < 0.05 was considered significant.
Results
HOG-LDL, but not N-LDL, suppresses the 
production of nitric oxide
Because nitric oxide is a key factor for maintaining vascular home-
ostasis, we tested the effect of HOG-LDL on nitric oxide produc-
tion in BAECs. Confluent BAECs were exposed to HOG-LDL at a
concentration of 100 g/ml, which is considered to be pathologi-
cally relevant to type 2 diabetes [25]. A 6-hr exposure to HOG-LDL
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decreased nitric oxide levels by 78%, whereas N-LDL had no
effect (Fig. 1A).
HOG-LDL, but not N-LDL, elicits a dose- and
time-dependent reduction in eNOS
Next, we investigated whether HOG-LDL reduces nitric oxide pro-
duction in BAECs by lowering total eNOS protein levels. No appre-
ciable change in total eNOS protein levels was observed at 3 hrs
of HOG-LDL (100 g/ml) incubation; however, total eNOS levels
were progressively decreased by 60% at 6 hrs and 80% at 9 hrs
after incubation (Fig. 1B).
The effects of HOG-LDL were also dose-dependent. As shown
in Fig. 1C, a 6-hr incubation with 100 g/ml or 200 g/ml HOG-
LDL reduced total eNOS levels by 60% and 80%, respectively.
Because the zinc-thiolate cluster of eNOS is essential for eNOS
activity and eNOS is active only as a dimer, we investigated
whether HOG-LDL may selectively decrease levels of eNOS
dimers. A 6-hr exposure to HOG-LDL (100 or 200 g/ml), but not
N-LDL, reduced the levels of eNOS dimers and monomers to a
similar degree (Fig. 1D).
HOG-LDL does not alter eNOS transcription or
directly degrade eNOS
To determine if reduction of eNOS protein levels by HOG-LDL was
due to inhibition of eNOS transcription, we tested the effect of
HOG-LDL treatment on eNOS mRNA levels in BAECs. Real time
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Fig. 1 HOG-LDL reduces nitric oxide and eNOS levels in endothelial cells. (A) Nitric oxide release in BAECs exposed to HOG-LDL or N-LDL (100 g/ml)
for 6 hrs n  4, *P < 0.01 versus control or N-LDL. (B) Western blot analysis of total eNOS in BAECs exposed to HOG-LDL (100 g/ml) for the indi-
cated times. n  3, **P < 0.01 versus 0 or 3 hrs time-point. (C) Concentration-dependent effects of HOG-LDL on total eNOS protein levels in BAECs.
n  4, **P < 0.01 versus untreated control or N-LDL (100 g/ml). (D) Western blot analysis of dimeric and monomeric eNOS in BAECs exposed to N-
LDL or the indicated concentration of HOG-LDL. *
,#P < 0.01. HOG-LDL versus untreated controls or n-LDL. (E) Real time qPCR analysis of eNOS in
BAECs treated with 100 g/ml N-LDL or HOG-LDL. PCR was performed with three pairs of independent eNOS primers, n  3 for each group. (F) Effect
of increasing concentrations of HOG-LDL on recombinant eNOS protein levels (total, monomeric and dimeric). HOG-LDL was incubated with recombi-
nant eNOS for 6 hrs, n  6 for each group.J. Cell. Mol. Med. Vol 13, No 9A, 2009
2903
PCR revealed that HOG-LDL exposure did not alter eNOS mRNA
levels (Fig. 1E), implying that HOG-LDL does not reduce eNOS
protein levels through inhibition of eNOS transcription.
Next, we investigated whether HOG-LDL reduces eNOS protein
in BAECs by direct oxidation of eNOS. To this end, purified recom-
binant bovine eNOS was incubated with HOG-LDL (50, 100 or 200
g/ml) for up to 6 hrs. Exposure of recombinant eNOS to HOG-
LDL (up to 200 g/ml) for 6 hrs did not alter the levels of total
eNOS, eNOS dimers or eNOS monomers (Fig. 1F). This suggests
that eNOS reduction cannot be attributed to direct destruction or
fragmentation of eNOS by HOG-LDL.
HOG-LDL-enhanced eNOS reduction is 
independent of 26S proteasomes
Because HOG-LDL did not alter eNOS levels in a cell-free system
and eNOS reduction in BAECs required at least a 3-hr incubation
with HOG-LDL, we speculated that HOG-LDL might reduce eNOS
levels by inducing eNOS degradation. Studies [26, 27] suggest
that eNOS is degraded by several mechanisms, including those
involving 26S proteasomes and calcium-dependent calpain. As
shown in Fig. 2A, exposure of BAECs to HOG-LDL (100 g/ml for
6 hrs) did not alter 26S proteasome activity. In addition, neither
HOG-LDL nor N-LDL affected the levels of protein ubiquintination
(Fig. 2B). Furthermore, eNOS reduction by HOG-LDL was unaf-
fected by co-administration of MG132, a potent proteasome
inhibitor (Fig. 2C). Taken together, these results suggest that
HOG-LDL-induced reduction in eNOS occurs independently of
26S proteasomes.
HOG-LDL increases calpain activity and eNOS
translocation to the cytoplasm, where calpains
reside
Calpains are Ca
2-dependent cysteine proteases which are impli-
cated in a large number of physiological processes [28, 29].
Calpain activity assays revealed that HOG-LDL markedly increased
the calpain activity in BAECs (Fig. 2D). Exposure of BAECs to HOG-
LDL for 6 hrs led to cleavage of the calpain substrate, caspase-12
[30], confirming that HOG-LDL induces calpain activation (Fig. 2E).
If eNOS is degraded by calpain, then a physical association
between these two proteins would be required. However, eNOS
exists predominantly in caveolae of the plasma membrane [31],
whereas calpains exist mainly in cytoplasm. Thus, we investigat-
ed whether HOG-LDL alters the subcellular localization of eNOS
in BAECs. After 2 hrs treatment, both immunocytochemical
staining (Fig. 2F) and Western blot analysis of membrane and
cytosolic fractions (Fig. 2G) revealed that HOG-LDL but not 
n-LDL (control) induced the translocation of eNOS from the
plasma membrane to the cytosol, where calpains mainly reside.
HOG-LDL also increased levels of Ser1177-phosphorylated
eNOS (data not shown).
Calpain inhibition prevents reduction of eNOS 
levels by HOG-LDL
As HOG-LDL increased calpain activity and eNOS export to the
cytoplasm, we determined if selective pharmacologic or genetic
inhibition of calpains attenuated the reduction in eNOS elicited by
HOG-LDL in BAECs. Calpain inhibitors alone did not alter the levels
of total, dimeric or monomeric eNOS (data not shown). However,
treatment of cells with calpain inhibitor III (MDL28170), calpeptin,
ALLM, ALLN or E64 prior to HOG-LDL exposure prevented reduc-
tion of total, dimeric and monomeric eNOS (Fig. 3A–C). To exclude
off-target effects of calpain inhibitors, we tested the effect of genet-
ic calpain inhibition on eNOS reduction by HOG-LDL. As the siRNA
against bovine calpain was not available, we performed these
experiments on HUVECs, which, like BAECs, express both eNOS
and calpain. Transfection of calpain-specific siRNA, but not control
siRNA, reduced calpain protein levels by 60% in HUVECs (Fig. 3D).
Calpain 1-specific siRNA partially prevented eNOS reduction by
HOG-LDL, whereas control siRNA had no effect (Fig. 3D).
HOG-LDL increases cytosolic Ca
2 levels
Calpain activity is strictly controlled by intracellular Ca
2, prompt-
ing us to test if calpain activation by HOG-LDL is Ca
2-dependent.
HOG-LDL (
50 g/ml) induced a pronounced elevation in intra-
cellular Ca
2 in BAECs, whereas N-LDL (100 g/ml) had no effect
(Fig. 4A). EGTA or either of the two potent Ca
2 channel blockers,
CoCl2 or LaCl3, significantly suppressed HOG-LDL-induced eleva-
tion in intracellular Ca
2 (Fig. 4B). Verapamil, a phenylalkylamine
Ca
2 channel blocker, had a similar effect (Fig. 4B). These results
imply that HOG-LDL increases cytosolic Ca
2 levels by opening
Ca
2 channels.
Inhibition of HOG-LDL-induced elevation in 
intracellular Ca
2 prevents eNOS degradation
Next, we investigated the Ca
2 dependence of HOG-LDL-induced
eNOS degradation. Decreasing free intracellular Ca
2 with 1.0–2.5
mM EGTA abolished eNOS reduction in BAECs exposed to 100
g/ml HOG-LDL (Fig. 4C). Similarly, Ca
2-channel blockers (i.e.
CoCI3 LaCI3, verapamil; Fig. 4D) or the intracellular Ca
2 chelator,
BAPTA (Fig. 4E and F), also significantly reversed HOG-LDL-induced
eNOS degradation. These results suggest that HOG-LDL promotes
eNOS degradation by increasing intracellular Ca
2 concentrations.
HOG-LDL increases the formation of ROS and the
membrane translocation of the p47
phox NAD(P)H
oxidase subunit
Recent studies by our laboratory and others suggest that ROS
cause the vascular injury induced by oxidized LDL (See review
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[32]). Thus, we hypothesized that ROS mediate the elevation in
intracellular Ca
2 and subsequent calpain activation by HOG-LDL.
In accordance with this hypothesis, HOG-LDL increased O2
 lev-
els by ~ 4-fold (P < 0.01), whereas N-LDL had no effect (Fig. 5A).
In addition, H2O2 was increased approximately twofold following 6
hrs of HOG-LDL treatment (Fig. 5B).
The formation of O2
 in HOG-LDL-exposed BAECs was signif-
icantly suppressed by inhibition of NAD(P)H oxidase with apoc-
ynin (data not shown), suggesting that NAD(P)H oxidase may
contribute to HOG-LDL-induced oxidative stress. Western blot
analysis of subcellular fractions revealed that HOG-LDL induced
p47
phox translocation from the cytosol to the plasma membrane
(Fig. 5C), a signature of NAD(P)H oxidase activation [33]. The
p47
phox membrane translocation was not seen in N-LDL-treated
BAECs. These results suggest that HOG-LDL activates NAD(P)H
oxidase, consistent with a previous report [34].
Inhibition of ROS formation attenuates 
HOG-LDL-induced elevation in intracellular Ca
2
Blocking Ca
2 influx with EGTA in HOG-LDL-treated BAECs not
only prevented eNOS degradation, but also dramatically reduced
O2
 and H2O2 production (Fig. 5D and E). Accordingly, inhibition
of NAD(P)H oxidase activity with apocynin or DPI attenuated
increases in intracellular Ca
2 (Fig. 5F) as well as eNOS degradation
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Fig. 2 HOG-LDL selectively activates calpain and induces cytoplasmic translocation of eNOS (A) Effect of HOG-LDL on 26S proteasome activity in
BAECs. n  3; ns, non significant difference for control versus HOG-LDL. (B) Effect of HOG-LDL on protein ubiquitination in BAECs, as determined by
Western blot analysis. n  3 for each group. (C) Western blot analysis of eNOS levels in BAECs exposed to HOG-LDL in the presence or absence of
MG132. The blot is a representative of four blots obtained from four separate experiments. *P < 0.01 HOG-LDL versus control; NS, no significant dif-
ference. (D) Calpain activity in BAECs treated with N-LDL (100 g/ml) or increasing concentrations of HOG-LDL for 6 hrs n  3, **P < 0.01 versus
untreated controls or n-LDL. (E) Effect of HOG-LDL on caspase 12 cleavage. The blot is representative of three separate experiments. (F) Confocal
images (400) of eNOS immunofluorescent staining in control and HOG-LDL-treated BAECs. Note the redistribution of eNOS from the plasma mem-
brane to the cytoplasm in the presence of HOG-LDL. (G) Western blot analysis for eNOS in membrane and cytosolic fractions isolated from control or
HOG-LDL-treated BAECs. n  3 for both groups.J. Cell. Mol. Med. Vol 13, No 9A, 2009
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in HOG-LDL-treated BAECs (Fig. 5G). Taken together, these results
suggest that exposure of endothelial cells to HOG-LDL triggers
production of ROS that, in turn, induce Ca
2 influx into the cyto-
plasm to stimulate calpain-dependent eNOS degradation.
HOG-LDL reduces aortic eNOS levels and 
impairs endothelial function in a 
calpain-dependent manner
Next, we determined whether HOG-LDL induces calpain-depend-
ent eNOS degradation in intact aortas. Isolated mouse aortas were
exposed to either N-LDL or HOG-LDL in the presence or absence
of MDL28170, and eNOS protein levels were measured. Exposure
of mouse aortas to MDL28170 alone (data not shown) or N-LDL
(Fig. 6A) did not affect eNOS levels. In contrast, exposure of aor-
tas to 100 g/ml HOG-LDL for 24 hrs reduced eNOS protein lev-
els by 75–80% (P < 0.05, Fig. 6A). Importantly, this reduction in
aortic eNOS levels was almost completely blocked by co-adminis-
tration of MDL28170 (Fig. 6A).
To investigate the role of HOG-LDL-induced calpain activation
in endothelial dysfunction, we tested the effect of N-LDL, HOG-
LDL and HOG-LDL  MDL28170 on endothelium-dependent and
-independent vasorelaxation under ex vivo conditions.
Acetylcholine induced concentration-dependent arterial vasodi-
latation in all treatment groups (Fig. 6B). MDL28170 alone has no
effect on vasorelaxation. However, Ach-induced vasodilatation
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Fig. 3 Pharmacological or genetic inhibition of calpain prevents reduction of eNOS by HOG-LDL. Western blot analysis of (A) total eNOS as well as (B)
dimeric and monomeric eNOS in BAECs exposed to HOG-LDL in the presence or absence of the indicated concentration of the calpain inhibitor III,
MDL28170. n  3, *P < 0.01 versus control, 
#P < 0.01 versus HOG-LDL-treated groups. (C) Effect of the other calpain inhibitors, calpeptin (20 M),
ALLM (20 M), ALLN (20 M) or E-64 (15 M), on total eNOS levels in HOG-LDL-exposed BAECs. *P < 0.01 versus untreated controls or n-LDL, 
#P <
0.01 versus HOG-LDL. (D) Western blot analysis of eNOS, and calpain 1 in HOG-LDL-stimulated HUVECs transfected with calpain 1 siRNA or scrambled
siRNA for 48 hrs. *P < 0.01 versus control, 
#P < 0.01 versus HOG-LDL. The blot is a representative of four blots obtained from four separate experiments.2906
was markedly attenuated in HOG-LDL-treated aortas compared to
N-LDL-treated aortas, with the maximum arterial relaxation
response in the HOG-LDL group being 42.2  4.6% and that in
the N-LDL group being 88.6  8.5% (n  4 per group, P < 0.01).
Further, MDL28170 significantly improved Ach-induced vasodi-
latation in the aortas treated with HOG-LDL. In contrast to Ach-
induced endothelium-dependent relaxation, SNP-induced
endothelium-independent vasorelaxation was identical among all
groups (Fig. 6C). Together, these data suggest that calpain partic-
ipates in HOG-LDL-induced endothelial dysfunction.
Discussion
Nitric oxide from eNOS plays essential role in maintaining vas-
cular homeostasis [35]. Reduced nitric oxide generation and/or
bioavailability have been implicated in the pathophysiology of
several disease states including coronary artery disease, hyper-
tension, diabetes and heart failure [36, 37]. eNOS is regulated
at the transcriptional, post-transcriptional and post-translation-
al level. Earlier studies suggest that increased intracellular Ca
2
and eNOS phosphorylation induce a rapid and transient eleva-
tion in eNOS activity, allowing for fast responses to changing
environmental conditions [38, 39]. Sustained alterations are
primarily due to changes in the expression of eNOS protein
[40]. In the present study, we have provided convincing evi-
dence that HOG-LDL perturbs intracellular Ca
2 homeostasis,
resulting in calpain-dependent degradation of eNOS and conse-
quent endothelial dysfunction. Our study strongly suggests that
HOG-LDL-induced eNOS degradation was associated with
endothelial dysfunction.
The calpains are a family of calcium-dependent proteases 
that act independently of the proteosome pathway and cleave
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Fig. 4 HOG-LDL increases intracellular Ca
2, and chelation of Ca
2 protects eNOS from degradation. (A) Intracellular Ca
2 concentrations in BAECs
exposed to HOG-LDL (100 g/ml) for 6 hrs, n  4, 
P < 0.01 versus untreated controls or n-LDL. (B) Effect of the Ca
2 channel blockers, CoCl2 (1
mM), LaCl3 (0.2 mM) or verapamil (1 mM), on HOG-LDL-induced Ca
2 influx. n  3, **P < 0.01 versus HOG-LDL. (C) Effect of EGTA (0.5–2.5 mM)
on HOG-LDL-induced reduction in total eNOS protein levels. n  3, *P < 0.01 versus control, 
#P < 0.01 versus HOG-LDL. (D) Effect of the Ca
2 chan-
nel blockers, CoCl3 (1 mM), LaCl3 (0.2 mM) or verapamil (1 mM), on total eNOS levels in HOG-LDL-treated BAECs. n  4, *P < 0.01 versus untreated
controls or n-LDL, 
#P < 0.01 versus HOG-LDL. (E). Intracellular Ca
2 levels in BAECs exposed to HOG-LDL for 6 hrs in the presence or absence of the
Ca
2 chelator, 5M of BAPT-AM (30-min. pre-incubation). n  4, *P < 0.01 versus control, 
#P < 0.01 versus HOG-LDL. (F) Effect of BAPT-AM (0.25–10
M) on total eNOS levels in HOG-LDL-exposed BAECs. n  4, *P < 0.01 versus control, 
#P < 0.01 versus HOG-LDL.J. Cell. Mol. Med. Vol 13, No 9A, 2009
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a number of cellular substrates, including kinases, phos-
phatases, transcription factors and cytoskeletal proteins. The
calpains are a family of Ca
2-dependent cysteine proteases,
which comprises three molecules: -calpain (calpain1), 
m-calpain and calpastatin, a third polypeptide functioning as
an inhibitor for two calpains. The -calpain is activated by
micromolar concentrations of Ca
2 whereas m-calpain activa-
tion requires millimolar concentrations of Ca
2 [41]. One
mechanism that may explain the relationship between inhibi-
tion of calpain activity and preservation of endothelial nitric
oxide in HOG-LDL treatment is altered post-translational regu-
lation of endothelial nitric oxide synthase. The evidence can be
summarized as follows. First, at doses over 50 g/ml, HOG-
LDL greatly elevated endothelial intracellular Ca
2. Second,
blockage of Ca
2 channels and chelation of intracellular Ca
2
protected eNOS from HOG-LDL-induced degradation. Third,
HOG-LDL increased calpain activity. Fourth, genetic inhibition
of calpain abolished HOG-LDL-induced eNOS degradation.
Finally, calpain inhibition restored Ach-induced endothelium-
dependent relaxation in isolated mouse aortas. In agreement
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Fig. 5 HOG-LDL-induced increases in intracellular Ca
2 and decreases in eNOS are ROS-dependent. (A) Superoxide (O2
) production in BAECs exposed
to HOG-LDL (100 g/ml, time course). n  4, *P < 0.01 Controls versus each time-point. (B) Hydrogen peroxide (H2O2) production in HOG-LDL-
exposed BAECs. n  4, **P < 0.01 versus control. (C) Effect of HOG-LDL on NADPH oxidase activation, as determined by membrane translocation of
p47
phox. BAECs exposed to agentension II (Ang II, 1 M) served as a positive control. The Western blot shown is representative of four blots obtained
from four separate experiments. (D) Effect of EGTA (2.5 mM, 1-hr pre-incubation) on HOG-LDL-induced O2
 release in BAECs. n  3, **P < 0.01 ver-
sus control, 
##P < 0.01 versus HOG-LDL. (E) H2O2 production in BAECs treated with HOG-LDL  EGTA. n  3, *P < 0.05 versus control, 
#P < 0.05 ver-
sus HOG-LDL. (F) Effect of apocynin (100 M) or DPI (10 M) on intracellular Ca
2 levels in BAEC exposed to HOG-LDL. n  3, **P < 0.01 versus
control, 
##P < 0.01 versus HOG-LDL. (G) Effect of apocynin or DPI on eNOS degradation by HOG-LDL (100 g/ml, 6 hrs), n  4, *P < 0.01 versus
untreated controls or n-LDL, 
#P < 0.01 versus HOG-LDL.2908
with our findings, several studies have demonstrated that
pharmacological inhibition of calpain preserves eNOS function
[42] and that calpain impairs association between eNOS and
the regulatory protein heat shock protein 90 [26], which is
also a calpain substrate [43]. Calpain 10 has recently been
linked to diabetes [44]. In addition, platelets from type 2 dia-
betic patients contain elevated Ca
2 and  -calpain activity
[45]. Thus, preservation of endothelial nitric oxide availability
could account for the beneficial effects of calpain inhibition on
HOG-LDL-induced vascular impairment. As levels of glycated
and oxidized LDL are elevated in patients with diabetes, these
findings might help uncover novel signalling pathways accel-
erating atherosclerosis in these patients.
In conclusion, we have demonstrated that [Ca
2]i and calpain
activity are increased in endothelial cells in response to HOG-LDL,
and that inhibition of [Ca
2]i rise and calpain activity attenuates
endothelial dysfunction induced by HOG-LDL via a eNOS/nitric
oxide dependent mechanism. Our findings uncovered a novel sig-
nalling pathway implicated in the pathophysiology of diabetic vas-
cular diseases such as atherosclerosis.
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Fig. 6 HOG-LDL-induced activation of calpain decreases eNOS levels and impairs endothelium-dependent relaxation in C57BL/6J mice aorta. (A)
Western blot analysis of total eNOS levels in aortas incubated with HOG-LDL (100 g/ml for 24 hrs) in the presence or absence of the calpain inhibitor
III, MDL28170 (20 M). n  4 in each group, **P < 0.01 versus N-LDL, 
P < 0.01 versus HOG-LDL. (B) Endothelium-dependent relaxation of HOG-
LDL-exposed aortas treated with or without MDL28170. n  5, *P < 0.05 for HOG-LDL versus untreated control or N-LDL, 
#P < 0.05 for HOG-LDL ver-
sus HOG-LDL  MDL28170. (C) Endothelium-independent relaxation in aortas treated with HOG-LDL  MDL28170. Results (mean  S.E.M.) are
expressed as the rate of relaxation to the pre-contraction, n  4.J. Cell. Mol. Med. Vol 13, No 9A, 2009
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